Visit the SMI-LabHut web site
Click on the advert above to visit the company web site

Product category: Ultrasound equipment and ultrasonic spectroscopy
News Release from: Akubio | Subject: Rapid4
Edited by the Laboratorytalk Editorial Team on 19 September 2006

Acoustic analysis of biomolecular
interactions

Request your FREE weekly copy of the Laboratorytalk email newsletter. News about Ultrasound equipment and ultrasonic spectroscopy and more every issue. Click here for details.

Based on resonant acoustic profiling (Rap), Rapid4 enables real-time label-free measurement and analysis of biomolecular interactions with the highest level of accuracy reproducibility and sensitivity

Akubio, the acoustic biosensors company, launched its Rapid4 biomolecular interactions analysis system at the 12th Annual SBS conference and exhibition, Seattle, Washington Based on the company's pioneering resonant acoustic profiling (Rap) technology, Rapid4 enables real-time label-free measurement and analysis of biomolecular interactions with the highest level of accuracy, reproducibility and sensitivity

Rapid4 is a flow-based system which reduces the need to purify samples and generates accurate kinetic, affinity and concentration measurements from complex mixtures, such as cell culture supernatants and periplasmic extracts.

A stand-alone, fully automated platform, Rapid4 requires minimal user intervention and is controlled via user-friendly software, typically processing an average of 400 samples per day.

Rap measures the oscillation of a resonating quartz crystal, which decreases in proportion to the mass of the molecules binding to its surface.

Researchers interrogate and evaluate the data using the intuitive Rapid Workbench software package.

Ian Campbell, business development director said: "Rapid4 allows users to work directly with complex samples, with minimal need for pre-assay purification or post-assay calibration.

"The system has been optimised for protein-protein interaction analysis and our application scientists continue to broaden the application areas of Rapid4".

Commenting on the launch, Andrew Mackintosh, CEO Akubio , said: "We are delighted to announce the launch of Rapid4, which represents an important step in the commercial development of Akubio and the delivery of an important new analytical tool to the pharmaceutical and general life science research community.

"While we are focussing on enabling the work of researchers, we believe that RAP will also have applications in broader markets.

"With our proprietary Rap acoustic technology, Akubio is set to become one of the world's leading biosensor companies.".

Akubio: contact details and other news
Email this article to a colleague
Register for the free Laboratorytalk email newsletter
Laboratorytalk Home Page

Search the Pro-Talk network of sites

Visit the SMI-LabHut web site